Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients

NCT05973344 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT05973344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05973344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Recruiting
Start date
February 9, 2024
Completion date
February 9, 2030
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer